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Ovarian cancer represents the fourth most frequent type of cancer among females and is the leading cause
of death from gynecological cancer in the western world. This review describes gene alterations in ovarian
cancer. Specific emphasis is placed on genetic alterations and the prevalence of TP53 (p53) gene
alterations in the distinct biological ovarian tumors (benign, borderline, and malignant) and histological
subtypes (serous, mucinous, endometrioid, clear cell), as well as in BRCA1-associated hereditary ovarian
cancer. Although multi-modality treatment regimens, including cytoreductive surgery and cisplatin-
containing combination chemotherapy, have usefully prolonged survival, the overall cure rate of the
disease has not changed dramatically. Ovarian cancer is difficult to eradicate completely by surgery and
many patients have only a partial response to postoperative chemotherapy and/or many will develop
chemotherapy resistance. All these important factors contribute to the poor prognosis of ovarian cancer
patients. In this review, the putative prognostic or predictive value of TP53 in ovarian cancer is
addressed. Hum Mutat 21:285–291, 2003. r 2003 Wiley-Liss, Inc.
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INTRODUCTION: OVARIAN CANCER
Ovarian cancer represents the fourth most frequent
type of cancer among females and is the leading cause
of death from gynecological cancer in the western
world. The risk of developing ovarian cancer in a
woman’s lifetime is estimated to be 1 in 70. The
incidence increases with age, reaching its peak in the
eighth decade. Ovarian cancer has a high frequency of
metastasis, yet generally remains localized within the
peritoneal cavity. Because of the absence of early
symptoms, approximately two-thirds of the patients
will have disease that has already spread beyond the
ovaries at the time of diagnosis. Extensive intra-
abdominal disease is difficult to eradicate completely
by surgery. Moreover, many patients have only a
partial response to postoperative chemotherapy and/or
many will develop chemotherapy resistance. All these
important factors contribute to the poor prognosis of
ovarian cancer patients.
The cause of ovarian cancer is unknown. One of
the strongest risk factors found in epidemiologic
studies is a positive family history of breast cancer
[Amos and Struewing, 1993]. Environmental factors
may play an important role in ovarian carcinogenesis,
although clear associations with industrial exposure to
carcinogens or to diagnostic and therapeutic radiation
have not been established. Endocrine factors are
thought to play an important role in the development
of ovarian cancer [Rao and Slotman, 1991]. For
example, the risk of ovarian cancer has been related to
high levels of gonadotropins in women in early
postmenopause [Rao and Slotman, 1991; Risch,
1998], to factors associated with excess androgenic
stimulation of ovarian epithelial cells [Risch, 1998]
and, although inconsistent, to exposure to fertility
drugs or hormone replacement therapy [Venn et al.,
1995; Risch, 1996; Weber, 1997; Garg et al., 1998;
Burmeister and Healy, 1998; Venn et al., 1999;
Rossing and Daling, 1999; Coughlin et al., 2000].
On the other hand, epidemiological studies have
demonstrated that reproductive factors, i.e., (multi)-
parity and oral contraceptive use, are associated with
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a decreased risk of ovarian cancer [Negri et al., 1991;
Franceschi et al., 1991a, b]. These observations have
led to the incessant ovulation hypothesis, where each
ovulation causes a minor trauma to the ovarian
surface epithelium by the formation of inclusion cysts
[Fathalla, 1971, 1972]. Aberrations in the repair
mechanism, in which wild-type TP53 (MIM#
191170) as the ‘‘guardian of the genome’’ [Lane,
1992] contributes directly and indirectly, might lead
to unrestrained proliferation and neoplasia.
Cancer of the ovary is a collection of diverse
pathologic entities that can be broadly characterized
as epithelial, germ cell, or stromal in origin. The
common malignant epithelial tumors account for more
than 90% of all ovarian cancers and are thought to
arise from the surface epithelium of the ovary and its
inclusion cysts [Woodruff, 1976; Scully, 1977]. These
epithelial neoplasms can be divided into three
biological subtypes: benign, low malignant potential
(borderline), and malignant tumors and in becoming
malignant, the ovarian surface epithelium can exhibit a
variety of mullerian-type differentiations, i.e., (in order
of decreasing frequency): serous, mucinous, endome-
trioid, and clear-cell tumors [Ozols et al., 1992].
GENETIC ALTERATIONS INOVARIAN CANCER
It is widely accepted that the pathway leading to
formation of a tumor is a multistep process involving
the accumulation of genetic alterations and many
oncogenes and tumor suppressor genes (TSG) have
been discovered. Only few of these have been studied
in (some) detail in ovarian cancer, but most studies
have been small and inconclusive and often no
mutations have been found in candidate TSGs. A
summary of some of the most intensively studied or
the most promising oncogenes and TSGs that may be
involved in ovarian cancer is listed in Table 1. In
general, TSG-studies have received far more attention
than oncogene studies in ovarian cancer and much of
the work has focused on identifying possible locations
where TSG may reside in the genome rather than the
actual study of known TSGs.
As shown in Table 1, loss of heterozygosity (LOH)
studies have indicated that chromosome 17 plays the
most significant role in ovarian tumor development.
On the short arm, LOH at 17p13.1 [Saretzki et al.,
1997; Eccles et al., 1992; Foulkes et al., 1993; Godwin
et al., 1994] as well as LOH at a more distal locus,
17p13.3 [Godwin et al., 1994; Phillips et al., 1993,
1996], has been observed in a high percentages of
these tumors. Mutation of the p53 gene TP53, which
maps to 17p13.1, is the most common genetic
alteration thus far in ovarian cancer, with mutations
being present in approximately 50% of advanced stage
ovarian carcinomas (see next paragraph). With
respect to chromosome 17p13.3, two candidate tumor
suppressor genes have been reported: OVCA1
(MIM# and OVCA2 (see DPH2L1); MIM#
603527) [Schultz et al., 1996]. Expression of OVCA1
TABLE 1. PutativeOncogenes andTumor SuppressorGenes Investigated inOvarianCancer
Gene
Chromosome
location Function % altered Spectrumofmutations
Oncogenes
c-FMS 5q33.3^q34 Receptor-like tyrosine kinase 57^100% Overexpression
CMYC 8q24 Transcription factor 30% Ampli¢cation, overexpression
K-RAS 12p12 Signal transduction 4^30% Simple (codon12,13 and codon 61)
HER-2/neu 17q21^q22 Receptor-like tyrosine kinase 8^40% Ampli¢cation, overexpression
AKT2 19q13.1^q13.2 Serine-threonine protein kinase 10^15% Ampli¢cation, overexpression
Tumor suppressor genes
FHIT 3p14.2 Unknown 4^8% Altered transcripts
APC 5q21 Binds a- and b-catenin:
involved in adhesion
Rare Multiplemutations
CDKN2/MTS1 9p21 Cyclin-dependent kinase
inhibitor
Rare Multiplemutations
PTEN 10q23.3 Phosphatase Rare Multiplemutations
WT1 11p13 Transcription factor None Mutations
ATM 11q22^q23 Protein kinase None Mutations
p27KIP1 12p13 Cyclin-dependent kinase
inhibitor
30^50% Loss of expression
None Mutations
TEL 12p13 Transcription factor None Mutations
RB1 13q14 Cell cycle regulator Rare Multiplemutations and loss of
expression
TP53 17p13.1 Cell cycle regulator; DNA
repair and apoptosis
50% Multiplemutations and
overexpression
OVCA1&2 17p13.3 Unknown ? Loss of expression
NF1 17q11.2 Downregulates the active form
of RAS
None Mutation
NM23 17q21.3 Nucleoside diphosphate kinase Rare Mutation
70% Enhanced expression
BRCA1 17q21 Transcription factor Rare Multiplemutations
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was shown to be reduced in ovarian tumor cell lines
and in ovarian tumor tissues compared to normal
ovarian tissues [Bruening et al., 1999]. Moreover,
overexpression of OVCA1 in the ovarian cancer cell
line A2780 was shown to suppress clonal outgrowth in
a colony formation assay [Bruening et al., 1999].
Interestingly, hypermethylation at chromosome
17p13.3 has also been reported in approximately
one-third of ovarian tumors and it was suggested that
hypermethylation precedes chromosome 17 loss
[Pieretti et al., 1995b].
On the long arm of chromosome 17, loss of 17q12-
q21 has frequently been observed [Foulkes et al.,
1993; Godwin et al., 1994; Cornelis et al., 1995; Miki
et al., 1994]. The breast and ovarian cancer suscept-
ibility gene BRCA1 (MIM# 113705) localizes to this
region (17q21). Germ-line mutations in BRCA1 are
responsible for approximately 50% of families that
have a predisposition to breast cancer and up to 80%
of those in which multiple cases of both breast and
ovarian cancer occur [Easton et al., 1995]. However,
mutations have proven to be infrequent in sporadic
forms of ovarian cancer [Merajver et al., 1995;
Takahashi et al., 1995; Berchuck et al., 1998; Tong
et al., 1999]. In addition to the BRCA1 locus, two
other regions of common loss have been identified on
chromosome 17, one at chromosome band 17q11.2
(NF1 locus) and the other at 17q23-24 (NM23/
NME1; MIM# 156490 and PHB/prohibitin; MIM#
176705) [Godwin et al., 1994; Jacobs et al., 1993;
Wertheim et al., 1996; Tangir et al., 1996]. Interest-
ingly, an increased sensitivity to cisplatin has been
observed in NM23-transfected breast (MDA-MB-
435) and ovarian carcinoma (OVCAR-3) cell lines
[Ferguson et al., 1996], but expression of NM23 could
not predict response to platinum-containing therapy
[Baekelandt et al., 1999]. Finally, many studies have
suggested that loss of the entire chromosome 17 may
be a relatively frequent event in ovarian tumors, thus
deleting TP53, BRCA1, and other potential tumor
suppressor genes in a single event [Tavassoli et al.,
1993; Pieretti et al., 1995a; Papp et al., 1996;
Quezado et al., 1999].
TP53 ALTERATIONS INOVARIAN CANCER IN
RELATION TODEGREEOF BIOLOGICAL
MALIGNANCYANDHISTOLOGICCLASSIFICATION
Benign epithelial ovarian tumors most frequently
develop in women between the ages of 20 and 60.
They are frequently large in size and are typically
cystic, hence the term cystadenoma. Benign tumors
almost always have a serous or mucinous histology.
Furthermore, benign serous tumors are more com-
monly bilateral than the other epithelial benign
tumors. Neither TP53 gene mutations nor its over-
expression have been described in these tumors
[reviewed by Shelling et al., 1995; Skilling et al.,
1996].
Ovarian borderline tumors, a distinct category with
the interchangeable terms cystadenomas of borderline
malignancy and carcinomas of low malignant potential
[Serov et al., 1973; FIGO, 1973], constitute approxi-
mately 15% of ovarian tumors. Patients with border-
line tumors are usually older than patients with benign
neoplasms but younger than women with frank
malignancies. The survival of patients with borderline
tumors is superior to patients with epithelial ovarian
cancer. The 5-year survival rate is about 95% and 20-
year survival is 80%. Most borderline tumors are of
the serous (60%) or mucinous (34%) histological
subtype, with endometrioid, clear cell, Brenner, and
mixed epithelial types making up the remaining 6%.
With respect to TP53 alterations, we and others have
shown that mutation of the TP53 gene is infrequent
(o5%) [Shelling et al., 1995; Skilling et al., 1996;
Schuyer et al., 1999; Teneriello et al., 1993; Wertheim
et al., 1994; Kupryjanczyk et al., 1995; Lee et al.,
1995]. TP53 immunostaining with at least one
monoclonal antibody (DO1 or DO7) was observed
in 10 of 28 (36%) tumor specimens analyzed by us.
Only 4 out of 27 (15%) tumor specimens, however,
showed immunopositivity with both monoclonal
antibodies. Surprisingly, the percentages of stained
tumor cells are much smaller than usually observed in
ovarian adenocarcinomas [Schuyer et al., 2001].
Several other studies have also shown that TP53
overexpression is rather uncommon in borderline
tumors and depending on cut-off levels and methods
used, the reported percentages varied from 4 to 24%
(mean between 10 and 15%) [Caduff et al., 1999;
Berchuck et al., 1994; Kupryjanczyk et al., 1994;
Eltabbakh et al., 1997; Skomedal et al., 1997].
Interestingly, the K-RAS gene, that has been im-
plicated as the most commonly mutated oncogene
associated with human tumors, is more commonly
mutated in borderline tumors and these mutations are
strongly associated (63%) with the mucinous cell type
[Schuyer et al., 1999; Caduff et al., 1994;
Enomotoet al., 1991; Mok et al., 1993; Ichikawa
et al., 1994].
Seven borderline components were studied by us
from tumors that included a carcinoma component.
An increased incidence of TP53 mutation and
accumulation was observed in these borderline
components compared to pure borderline tumors,
suggesting that these tumors indeed progress to the
malignant invasive phenotype through an accumula-
tion of genetic alterations (Schuyer, unpublished
data). However, the number is small. It would be
interesting, especially in these tumors, to study both
the borderline and the invasive component. Micro-
dissection techniques, however, are a prerequisite.
In conclusion, although TP53 is the most com-
monly mutated tumor suppressor gene in human
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cancer, TP53 gene alteration is infrequent in border-
line ovarian tumors.
Malignant tumors are characterized by infiltrative
destructive growth. They often present as solid masses
with areas of necrosis. These tumors are uncommon in
younger women under age 35. Symptoms often
present late, when the tumor has already spread
beyond the ovary and seeded the peritoneum. The
most important determinant of clinical outcome is the
surgicopathologic stage at the initial time of diagnosis.
The staging system defined by the International
Federation of Gynecologic Oncologists [FIGO, 1971;
Cannistra, 1993]. For patients with stage I disease
survival rates have been reported over 90% [Young
et al., 1990]. Patients with stage III disease, in which
the disease has spread outside the pelvis into the
abdominal cavities, have a 5-year survival rate of
approximately 20% whereas patients with stage IV
disease have a survival rate of o5% [Ozols et al.,
1992; Makar et al., 1995]. The prevalence of TP53
gene alterations appears to raise with increasing stage.
TP53 gene mutations occur more often in stage III
and IV ovarian cancers when compared to stage I and
II, i.e., in 58% versus 37% in stage III/IV and in stage
I/II, respectively [as reviewed by Shelling et al., 1995;
on 900 cases]. Moreover, as reviewed by Skilling et al.
[1996] on 850 primary ovarian tumors, TP53 gene
mutations or overexpression are more prevalent in
serous primary ovarian cancers, i.e., in 58% and 59%
of the cases, respectively. The percentage of TP53
gene mutations was reported to be lower for
endometrioid, mucinous, and clear-cell ovarian
tumors, i.e., 28%, 16%, and 10%, respectively, but
slightly higher when using immunohistochemical
techniques, i.e., 37% in the endometrioid and 31%
in mucinous tumor types (the number for clear-cell
tumors is too low).
Hereditary ovarian cancer, which comprises ap-
proximately 10% of epithelial ovarian cancers, has
been described in association with three autosomal
dominant syndromes: hereditary breast and ovarian
cancer (HBOC), hereditary site-specific ovarian
cancer (HOC), and hereditary nonpolyposis colon
cancer syndrome (HNPCC, MIM# 114500). In 80%
of families with inherited breast and ovarian cancer
and in nearly half of familial breast cancers, linkage to
the BRCA1 gene exists. Data have shown that
BRCA1 and TP53 physically associate and that
BRCA1 enhances TP53-dependent gene expression
by acting as a co-activator, whereas mutant forms of
BRCA1 lacking the second BRCA1 C-terminal
(BRCT) domain show reduced TP53-mediated tran-
scriptional activation [Ouchi et al., 1998; Zhang et al.,
1998]. The cooperative action of BRCA1 and TP53 is
further strengthened by the observation that early
embryonic lethality of brca1-deficient mice could be
partially rescued by tp53 or p21 null mutations
[Hakem et al., 1996]. Although there are few data
available on TP53 in hereditary ovarian cancers, TP53
alterations indisputably occur more often in BRCA1-
associated ovarian tumors than in sporadic ovarian
tumors, as summarized in Table 2.
Several studies have shown that TP53 is also more
frequently inactivated in BRCA1-associated breast
tumors than in sporadic breast cancers [reviewed in
Schuijer et al., 1999; and Gasco et al., this issue]. This
implies that loss of TP53 function is a critical event in
the molecular pathogenesis of BRCA1-associated
TABLE 2.TP53Mutations and/or ProteinAccumulation inBRCA1-AssociatedOvarianTumors
Referencea
TP53
mutationb %
TP53
accumulationc %
TP53 mutation
and accumulation
combined % Remarks
Crooket al. [1997] 1/1 N.D. N.A. Type ofBRCA1mutations not
described
Schlichtholz et al. [1998] 0/3 1/2 1/2 TP53 exons 4^9 analyzed
Rhei et al. [1998] 24/29 83 21/29 72 28/29 97 TP53 exons 2^11analyzed;
93% Ashkenazi
JewishBRCA1 foundermutations:
185delAG (76%),5382insC (17%)d
Ramus [2000] 18/30 60 21/30 70 N.A. ^
Schuijer [2000] 7/7 100 N.D. N.A. TP53 exons 4^10 analyzed; Dutch
BRCA1 foundermutations
Ravid et al. [2000] N.D. 80 17/27 63 N.A. OnlyBRCA1 foundermutation
185delAG tested
Buller [2001] 16/20 N.D N.A TP53 has di¡erentmutation
spectrum
aOnly those papers are listed that clearly de¢neBRCA1mutations.
bA direct but rather tedious approach to examineTP53 dysfunction is mutation analysis of the gene.Themajority ofTP53mutations localize to
the sequence-speci¢c DNA-binding region comprising exons 5^8,which often leads investigators to study only this part of the gene. A detailed
database ofTP53 mutations in all human cancers including sporadic breast and ovarian cancers can be found on the website http://perso.cur-
ie.fr/Thierry.soussi [Beroud and Soussi, 2003].
cA rapid and simple approach to study theTP53 gene is to examineTP53 protein expression. In itswild-type form,TP53 has a very short half-life.
Themajority ofTP53mutations (approximately 80%) result in stabilization of the protein, which allows for immunological detection.
dAlso referred to as 187delAG and 5385insC. A database of BRCA1 mutations can be found on www.nhgri.nih.gov/Intramural___research/
Lab___transfer/bic/index.html; N.D., not determined; N.A., not applicable.
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breast and ovarian tumors. Although the incidence of
TP53 abnormalities in BRCA1-associated tumors is
high (70–80%, Table 2), not all BRCA1-associated
ovarian tumors seem to harbor a TP53 aberration.
TP53 function may be eliminated through other
mechanisms, such as hypermethylation or mutation of
the TP53 promoter region or large chromosomal
deletions involving the TP53 locus. Besides, we
speculate that other genes, most likely involving the
TP53 checkpoint mechanism, might be involved.
Based on the hypothesis by Kinzler and Vogelstein
[1997], we would like to propose a role for BRCA1 as
a caretaker whereas TP53 appears to fit the gate-
keeper class more explicitly in BRCA1-associated
ovarian cancer.
TP53 ALTERATIONS INOVARIAN CANCER IN
RELATION TO PROGNOSIS
Although multimodality treatment regimens, in-
cluding cytoreductive surgery and cisplatin-containing
combination chemotherapy have usefully prolonged
survival, the overall cure rate of the disease has not
changed dramatically. The 5-year survival for patients
with localized disease is approximately 80%, whereas
only 20% of the patients diagnosed with disease that
has spread outside the pelvis are alive after 5 years
[Cannistra, 1993; Friedlander, 1998; Makar et al.,
1995]. Interval debulking surgery has resulted in a
slight improvement in survival rates for patients with
advanced ovarian cancer [van der Burg et al., 1995]
but survival rates are still poor. Current routinely used
prognostic factors are mainly based on clinico-
pathological criteria, which are subject of inter- and
intra-observer differences. Therefore, more quantita-
tive approaches to identify new biologic factors
associated with clinical prognostic significance may
decrease the subjectivity frequently associated with
prognostic factors. Numerous molecular genetic
lesions have been identified, which may be useful for
prognostic characterization of ovarian cancer patients.
Although several genes involved in ovarian cancer
have been identified, many more genes remain to be
discovered and the clinical significance of the cancer
genes already known is still in its infancy.
TP53 is one of the most studied genes in relation to
prognosis and prediction of response to (adjuvant)
chemotherapy of ovarian cancer, with about 150
papers so far written (PubMed update 2002, keywords:
TP53/p53; prognosis; ovarian cancer). These reports,
on the relation between TP53 status and disease
progression or survival, have appeared in the last 10
years, however, conflicting conclusions were reached
on the prognostic value of TP53 in ovarian cancer.
Although there seems to be a trend that TP53 status,
as determined by immunohistochemical analysis and
mainly in univariate analyses, might be of prognostic
value, these data have to be interpreted with caution.
The lack of unanimity between authors may be
explained by: 1) differences in the techniques used for
the analysis of TP53 status (for example, immunohis-
tochemical analysis with different antibodies on frozen
or paraffin-embedded tissues using different cutoff
levels, ELISA, PCR-single-strand conformational
polymorphism/constant denaturing gel electrophoresis
analysis of primarily exons 5–8, or cDNA sequencing
of the entire gene); 2) patient sample size; 3)
biological and/or histological ovarian tumor subset
analyses; 4) retrospective nature of the studies; 5)
different treatments of the patient population; 6)
different (modern) prognostic covariates used in the
multivariate analyses; 7) the subjectivity inherent to
some approaches; and 8) publication bias. Despite
these uncertainties, a phase I trial of intraperitoneal
delivery of ONYX-015, which allows selective replica-
tion in and lysis of p53-deficient tumor cells, in
patients with recurrent epithelial ovarian cancer is
ongoing [Vasey et al., 2002].
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